Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Industry Analysis - Changing Dynamics in Worldwide Psychiatric Franchises

Published by: Decision Resources

Published: Dec. 15, 2006 - 18 Pages

Price reduced due to age.

Table of Contents



Executive Summary

Strategic Considerations

Stakeholder Implications




Overview

Psychiatric Diseases

Worldwide Psychiatric Markets—Top Brands

Major Psychiatric Franchises




Big Pharma Franchises

AstraZeneca

GlaxoSmithKline

Eli Lilly

Johnson & Johnson

Novartis

Pfizer

Sanofi-Aventis

Wyeth




Midsize Pharma Franchises




Generics Franchises




Recent Psychiatric Deals




Outlook




Figures

1. Total Prevalent Cases of Select Patient Populations, 2006

2. Blockbuster Psychiatric Drugs, 2005

3. Major Worldwide Psychiatric Franchises—Big and Midsize Pharma, 2005

4. Worldwide Generics Psychiatric Franchises, 2005

5. Genotype-Based Drug Doses for Antidepressants




Tables

1. Select Psychiatric Deals, 2005-2006

Abstract

Introduction

The treatment of psychiatric diseases is hardly straightforward; patients often try many different drug regimens and combinations in order to identify an optimal course of therapy. Although the long-term goal in treating psychiatric diseases is to halt disease progression and to prevent the onset of permanent damage, a more attainable step will be to individualize treatment for patients using available drugs.

Get the Answers You Need to Shape Your Strategy

Psychiatric franchises are transforming as industry players concede potential opportunities to others, capitalize on available opportunities, or challenge others for coveted opportunities. What are the major psychiatric franchises? What characteristics of the psychiatric industry make for a dynamic market?

Few innovative psychiatric drugs are in development; however, psychiatric disease markets are substantial. Yet, big pharma’s single-minded focus on developing the next blockbuster drug concedes a large portion of pharmaceutical drug markets to midsize pharma companies. Which midsize companies have the largest psychiatric franchises, and how are they fi lling the market space conceded by big pharma?

Identifying the genetic variations associated with psychiatric diseases will be essential in the development of drugs that provide personalized treatment options for patients. What pharmacogenomics-based agents are currently in development?

Scope
  • Psychiatric diseases: overview and prevalence of the major psychiatric diseases in the seven major pharmaceutical markets (United States, Europe [France, Germany, Italy, Spain, and the United Kingdom], and Japan).
  • Worldwide psychiatric markets: a description of the psychiatric pharmaceutical industry and the top-selling psychiatric drug brands of 2005.
  • Major psychiatric franchises: dominant big pharma, midsize pharma, and generics franchises.
  • Psychiatric deals: a description of the recent license and collaboration deals in the psychiatric industry.
  • Outlook: the impact of industry dynamics on pharmaceutical companies.


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2009